- Home
- GOSS vs BWAY Comparison
GOSS vs BWAY Comparison
Compare GOSS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- BWAY
- Stock Information
- Founded
- GOSS 2015
- BWAY 2003
- Country
- GOSS United States
- BWAY Israel
- Employees
- GOSS N/A
- BWAY N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- GOSS Health Care
- BWAY Health Care
- Exchange
- GOSS Nasdaq
- BWAY Nasdaq
- Market Cap
- GOSS 188.6M
- BWAY 207.4M
- IPO Year
- GOSS 2019
- BWAY 2019
- Fundamental
- Price
- GOSS $0.84
- BWAY $8.24
- Analyst Decision
- GOSS Strong Buy
- BWAY Strong Buy
- Analyst Count
- GOSS 4
- BWAY 3
- Target Price
- GOSS $7.50
- BWAY $13.17
- AVG Volume (30 Days)
- GOSS 1.5M
- BWAY 31.1K
- Earning Date
- GOSS 05-06-2025
- BWAY 05-07-2025
- Dividend Yield
- GOSS N/A
- BWAY N/A
- EPS Growth
- GOSS N/A
- BWAY N/A
- EPS
- GOSS N/A
- BWAY 0.09
- Revenue
- GOSS $114,701,000.00
- BWAY $41,016,000.00
- Revenue This Year
- GOSS N/A
- BWAY $349.63
- Revenue Next Year
- GOSS $172.31
- BWAY $27.16
- P/E Ratio
- GOSS N/A
- BWAY $54.30
- Revenue Growth
- GOSS N/A
- BWAY 29.04
- 52 Week Low
- GOSS $0.50
- BWAY $4.61
- 52 Week High
- GOSS $1.55
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- GOSS 37.58
- BWAY 32.71
- Support Level
- GOSS $0.80
- BWAY $8.29
- Resistance Level
- GOSS $0.88
- BWAY $8.58
- Average True Range (ATR)
- GOSS 0.10
- BWAY 0.53
- MACD
- GOSS -0.01
- BWAY -0.05
- Stochastic Oscillator
- GOSS 20.24
- BWAY 14.81
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.